A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/616 (2006.01) A61K 31/167 (2006.01) A61K 31/522 (2006.01) A61K 31/60 (2006.01) A61P 25/06 (2006.01) A61P 29/00 (2006.01)
Patent
CA 2296492
The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. In accordance with the present invention, the use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack, prior to the onset of the migraine- associated symptoms, aborting the symptoms of migraine attack prior to the onset of severe, throbbing migraine pain, and aborting migraine pain after a migraine has fully developed. In accordance with the present invention, the efficacy of the APAP/ASA/CAF combination treatment in reducing and eliminating migraine pain is at a parity with the efficacy of sumatriptan, a known, but dissimilar, anti-migraine agent, used at similar dosing regimens. Use of the APAP/ASA/CAF combination composition treatment at the unit dose also advantageously reduces/obviates the need of the migraine sufferer to re-dose or re-medicate at the end of the dosing period in accordance with the present invention.
L'invention porte également sur une composition en vente libre sans danger et économique d'acétaminophène, d'aspirine et de caféine (APA/ASA/CAF) traitant la migraine et le groupe de symptômes caractéristiques associés tels que la nausée, la photophobie, la phonophobie, et certaines invalidités fonctionnelles. Selon l'invention la combinaison APA/ASA/CAF permet de traiter les prodromes de l'accès de migraine avant l'apparition des symptômes, d'enrayer lesdits symptômes avant l'établissement de fortes douleurs lancinantes, et d'arrêter la migraine pleinement établie. L'efficacité de la combinaison APA/ASA/CAF pour réduire ou supprimer la douleur est à égalité à dose similaire avec celle du sumatripan, agent de traitement de la migraine connu mais différent. La prise d'une dose unitaire de la composition réduit ou supprime la nécessité pour le patient de prise d'une nouvelle dose ou de médicaments additionnels à la fin de la période de dosage.
Armellino Joseph J.
Koslo Randy J.
Bristol-Myers Squibb Company
Gowling Lafleur Henderson Llp
Novartis Ag
LandOfFree
Use of compositions containing the combination of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of compositions containing the combination of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compositions containing the combination of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2069420